Effect of DNA methylation at the CTLA4 gene on the clinical status of autoimmune thyroid diseases

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2024-08-13 DOI:10.1016/j.clim.2024.110338

Hiroki Ohtani , Naoya Inoue , Yoshinori Iwatani , Yuri Takeno , Yuya Arakawa , Yoh Hidaka , Mikio Watanabe

{"title":"Effect of DNA methylation at the CTLA4 gene on the clinical status of autoimmune thyroid diseases","authors":"Hiroki Ohtani , Naoya Inoue , Yoshinori Iwatani , Yuri Takeno , Yuya Arakawa , Yoh Hidaka , Mikio Watanabe","doi":"10.1016/j.clim.2024.110338","DOIUrl":null,"url":null,"abstract":"<div><p>The pathogenesis and manifestation of autoimmune thyroid diseases (AITDs), Graves' disease (GD), and Hashimoto's disease (HD) are associated with T cell activation. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) plays a crucial role in the regulation of T cell activation. DNA methylation levels of eight CpG sites in the <em>CTLA4</em> gene and expression levels of soluble CTLA-4 were examined. Methylation levels of +22 CpG and CT60 CpG-SNPs in patients with GD and HD with the CT60 GG genotype were lower than those in control subjects. Methylation levels of the-15 CpG sites were lower in patients with intractable GD than those in GD patients in remission. These results suggest that demethylation of +22 CpG and CT60 CpG-SNPs may be associated with susceptibility to GD and HD in subjects with the <em>CTLA4</em> CT60 GG genotype, and that demethylation of −15 CpG may be associated with the intractability of GD.</p></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"267 ","pages":"Article 110338"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521661624004479/pdfft?md5=0c1dbb4895daac5324e81618f423b492&pid=1-s2.0-S1521661624004479-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661624004479","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The pathogenesis and manifestation of autoimmune thyroid diseases (AITDs), Graves' disease (GD), and Hashimoto's disease (HD) are associated with T cell activation. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) plays a crucial role in the regulation of T cell activation. DNA methylation levels of eight CpG sites in the CTLA4 gene and expression levels of soluble CTLA-4 were examined. Methylation levels of +22 CpG and CT60 CpG-SNPs in patients with GD and HD with the CT60 GG genotype were lower than those in control subjects. Methylation levels of the-15 CpG sites were lower in patients with intractable GD than those in GD patients in remission. These results suggest that demethylation of +22 CpG and CT60 CpG-SNPs may be associated with susceptibility to GD and HD in subjects with the CTLA4 CT60 GG genotype, and that demethylation of −15 CpG may be associated with the intractability of GD.

查看原文本刊更多论文

CTLA4 基因的 DNA 甲基化对自身免疫性甲状腺疾病临床状况的影响。

自身免疫性甲状腺疾病（AITD）、巴塞杜氏病（GD）和桥本氏病（HD）的发病机制和表现与T细胞活化有关。细胞毒性T淋巴细胞相关抗原4（CTLA-4）在T细胞活化的调控中起着至关重要的作用。研究人员检测了 CTLA4 基因中八个 CpG 位点的 DNA 甲基化水平和可溶性 CTLA-4 的表达水平。具有 CT60 GG 基因型的 GD 和 HD 患者 +22 CpG 和 CT60 CpG-SNPs 的甲基化水平低于对照组。难治性 GD 患者 15 CpG 位点的甲基化水平低于缓解期 GD 患者。这些结果表明，+22 CpG和CT60 CpG-SNPs的去甲基化可能与CTLA4 CT60 GG基因型受试者对GD和HD的易感性有关，而-15 CpG的去甲基化可能与GD的难治性有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.